A Phase 3 interventional study of Venetoclax and Bortezomib in Relapsed/Refractory Multiple Myeloma, sponsored by AbbVie. Completed at 97 sites in 16 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-08-22.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing venetoclax in Multiple Myeloma — 4 open to participants now, 9 under way, 2 of them phase 3. venetoclax · Multiple Myeloma.
Among the 20 studies testing venetoclax in Multiple Myeloma, this one has the largest enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 4th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →4 of the 20 studies testing venetoclax in Multiple Myeloma are open now, in 3 countries. Recruiting first, the newest first:
Oncotherapeutics · Sites in United States
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
University of Miami · Sites in United States
Ages 18+
Melbourne Health · Sites in Australia
Ages 18–75
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 291 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 42 across the 20 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
40 studies in Multiple Myeloma by AbbVie: 7 open now, 17 under way, 5 of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 15th registered.
AbbVie’s Multiple Myeloma studies by the year they started, since 2005.
4 of the studies testing venetoclax in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05391750Emory UniversityVenetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | 2027-02-12 |
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT02899052AbbVieStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing venetoclax in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 40 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Non-secretory multiple myeloma, active plasma cell leukemia i.e., either 20% of peripheral white blood cells or greater than 2.0 X 10\^9/liter (L) circulating plasma cells by standard differential, Waldenstrom's macroglobulinemia, amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), known Human Immunodeficiency Viral () infection, active or C infection based on blood screen tests, significant cardiovascular disease, including uncontrolled angina, severe or uncontrolled arrhythmia, recent myocardial infarction within 6 months of randomization, or congestive heart failure (NYHA) Class ≥ 3, major surgery within 4 weeks prior to randomization, acute infections requiring parenteral therapy (antibiotic, antifungal, or antiviral) within 14 days prior to randomization, peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to randomization, uncontrolled diabetes or uncontrolled hypertension within 14 days prior to randomization, any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23
Drug: Venetoclax · Drug: Bortezomib · Drug: Dexamethasone
Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \& 23
Drug: Bortezomib · Drug: Dexamethasone · Drug: Placebo for venetoclax
Participants self-administered venetoclax tablets by mouth QD in combination with bortezomib. Venetoclax was to be given before other agents administered on the same day, if applicable. Each venetoclax dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
Also known as: VENCLEXTA, VENCLYXTO
Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.
Also known as: Velcade
Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).
Participants self-administered placebo tablets by mouth QD in combination with bortezomib. Placebo was to be given before other agents administered on the same day, if applicable. Each placebo dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
Progression-free Survival (PFS)
PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.
Time frame: Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Very Good Partial Response (VGPR) or Better Response Rate
The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC) was computed.
Time frame: Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Progression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression
PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) per investigator assessment or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology. BCL-2 expression was determined through central laboratory testing by immunohistochemistry (IHC) and based on a pre-specified scoring algorithm. High clinical score of 2+: ≥50% of tumor cells with moderate or higher cytoplasmic staining but \< 50% of tumor cells with strong staining intensity; high clinical score of 3+: ≥50% of tumor cells with strong cytoplasmic staining.
Time frame: Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Duration of Response (DOR)
DOR is defined as the number of days from the participant's date of first documented response (partial response \[PR\] or better) to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan-Meier methodology.
Time frame: Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain
The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score
PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Overall Survival (OS).
OS is defined as the number of days from the date of randomization to the date of death due to any cause. All events of death were to be included, regardless of whether the event occurred while the participant was still taking study drug or after the participant discontinued study drug. If a participant is not known to have died, OS was censored at the date of last contact. The distribution of OS was estimated using Kaplan-Meier methodology.
Time frame: Median duration of follow-up was 45.6 months for the venetoclax group and 45.6 months for the placebo group
Time to Progression (TTP)
TTP is defined as the number of days from the date of randomization to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan-Meier methodology.
Time frame: Median time on follow-up up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Overall Response Rate (ORR)
Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC).
Time frame: Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Minimal Residual Disease (MRD) Negativity Rate
MRD negativity rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any time point after randomization and before progression or starting subsequent therapy. MRD negativity was defined at 10\^-5 threshold (less than one residual myeloma cell per 10\^5 total nucleated cells) as measured by centralized testing of bone marrow aspirate by Next Generation Sequencing (NGS). MRD positive participants include those of which all tested samples were found to be MRD positive or indeterminate. Participants with missing or unevaluable MRD status were considered as MRD positive.
Time frame: Assessed at Screening; to confirm a stringent Complete Response (sCR) or Complete Response (CR); at 6 months and 12 months post-confirmed CR/sCR
| Milestone | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Started | 194 | 97 |
| Completed | 0 | 0 |
| Not completed | 194 | 97 |
| Withdrew: Withdrew consent | 27 | 11 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 78 | 36 |
| Withdrew: Study terminated by sponsor | 67 | 47 |
| Withdrew: Other, not specified | 20 | 3 |
| Withdrew: Participant missing reason for study discontinuation | 1 | 0 |
PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.
| months | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Progression-free Survival (PFS) | 23.2 (15.3 to 27.5) | 11.5 (9.6 to 15.0) |
The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC) was computed.
| percentage of participants | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Very Good Partial Response (VGPR) or Better Response Rate | 60.3 (53.1 to 67.2) | 38.1 (28.5 to 48.6) |
PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) per investigator assessment or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology. BCL-2 expression was determined through central laboratory testing by immunohistochemistry (IHC) and based on a pre-specified scoring algorithm. High clinical score of 2+: ≥50% of tumor cells with moderate or higher cytoplasmic staining but \< 50% of tumor cells with strong staining intensity; high clinical score of 3+: ≥50% of tumor cells with strong cytoplasmic staining.
| months | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Progression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression | 23.8 (19.5 to 34.7) | 11.4 (9.1 to 15.0) |
DOR is defined as the number of days from the participant's date of first documented response (partial response \[PR\] or better) to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan-Meier methodology.
| months | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Duration of Response (DOR) | NA (22.8 to NA) | 12.8 (10.6 to 15.5) |
The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.
| units on a scale | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Cycle 3, Day 1 | -0.6 ± 2.59 | -0.5 ± 2.46 |
| Cycle 5, Day 1 | 0.0 ± 2.65 | -0.2 ± 3.15 |
| Cycle 7, Day 1 | -0.1 ± 2.56 | 0.2 ± 2.98 |
| Cycle 9, Day 1 | -0.2 ± 3.11 | 0.0 ± 2.88 |
| Cycle 11, Day 1 | -0.4 ± 2.57 | 0.1 ± 3.45 |
| Cycle 13, Day 1 | -0.2 ± 2.71 | -0.1 ± 3.22 |
| Cycle 15, Day 1 | -0.2 ± 2.92 | -0.0 ± 3.08 |
| Cycle 17, Day 1 | -0.3 ± 2.54 | -0.1 ± 2.06 |
| Cycle 19, Day 1 | -0.1 ± 2.59 | -0.2 ± 1.95 |
| Cycle 21, Day 1 | -0.1 ± 2.39 | -0.3 ± 2.89 |
| Cycle 23, Day 1 | -0.0 ± 3.20 | -0.2 ± 2.61 |
| Cycle 25, Day 1 | 0.4 ± 2.65 | 0.2 ± 3.00 |
| Cycle 27, Day 1 | 0.2 ± 2.53 | 0.1 ± 1.92 |
| Cycle 29, Day 1 | -0.2 ± 2.83 | 0.3 ± 2.15 |
| Cycle 31, Day 1 | 0.0 ± 3.11 | 0.6 ± 1.33 |
| Cycle 33, Day 1 | -0.2 ± 2.88 | 0.4 ± 1.40 |
| Cycle 35, Day 1 | 0.1 ± 2.77 | -0.2 ± 1.33 |
| Cycle 37, Day 1 | 0.4 ± 2.78 | 1.5 ± 2.65 |
| Cycle 39, Day 1 | 0.1 ± 2.70 | -0.3 ± 1.15 |
| Cycle 41, Day 1 | 0.1 ± 3.00 | 0.3 ± 1.15 |
| Cycle 43, Day 1 | -0.1 ± 3.07 | 0.5 ± 0.71 |
| Cycle 45, Day 1 | -0.7 ± 3.64 | 1.0 ± 0.00 |
| Cycle 47, Day 1 | -2.8 ± 3.77 | 1.0 |
| Final visit | 0.3 ± 3.28 | 0.4 ± 3.55 |
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.
| units on a scale | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Cycle 3, Day 1 | -5.0 ± 18.22 | -4.6 ± 19.50 |
| Cycle 5, Day 1 | -3.9 ± 18.38 | -7.8 ± 21.50 |
| Cycle 7, Day 1 | -6.1 ± 20.19 | -8.6 ± 19.76 |
| Cycle 9, Day 1 | -3.5 ± 19.54 | -8.0 ± 20.01 |
| Cycle 11, Day 1 | -1.5 ± 15.92 | -7.5 ± 18.46 |
| Cycle 13, Day 1 | -3.2 ± 16.57 | -8.8 ± 22.85 |
| Cycle 15, Day 1 | -2.3 ± 18.72 | -7.3 ± 22.27 |
| Cycle 17, Day 1 | -1.8 ± 16.23 | -8.6 ± 19.90 |
| Cycle 19, Day 1 | -2.5 ± 19.30 | -7.0 ± 19.35 |
| Cycle 21, Day 1 | -1.5 ± 17.81 | -8.5 ± 20.43 |
| Cycle 23, Day 1 | -3.4 ± 20.32 | -7.5 ± 20.53 |
| Cycle 25, Day 1 | -3.8 ± 17.28 | 0.5 ± 23.95 |
| Cycle 27, Day 1 | -8.6 ± 21.69 | -3.3 ± 18.44 |
| Cycle 29, Day 1 | -8.7 ± 21.25 | -4.0 ± 19.81 |
| Cycle 31, Day 1 | -2.8 ± 17.98 | 2.2 ± 18.56 |
| Cycle 33, Day 1 | -4.0 ± 22.76 | -4.8 ± 23.64 |
| Cycle 35, Day 1 | -7.0 ± 16.64 | 4.4 ± 18.70 |
| Cycle 37, Day 1 | -7.5 ± 22.49 | 15.0 ± 14.78 |
| Cycle 39, Day 1 | -10.1 ± 18.80 | 8.9 ± 10.18 |
| Cycle 41, Day 1 | -13.0 ± 25.65 | 13.3 ± 23.09 |
| Cycle 43, Day 1 | -7.8 ± 23.12 | 13.3 ± 18.86 |
| Cycle 45, Day 1 | -1.3 ± 10.33 | 13.3 ± 18.86 |
| Cycle 47, Day 1 | 0.0 ± 14.40 | 0.0 |
| Final visit | -11.8 ± 22.85 | -10.0 ± 21.52 |
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.
| units on a scale | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Cycle 3, Day 1 | -1.9 ± 22.75 | -2.2 ± 22.63 |
| Cycle 5, Day 1 | -5.1 ± 26.74 | -2.5 ± 23.54 |
| Cycle 7, Day 1 | -8.3 ± 26.76 | -6.7 ± 24.56 |
| Cycle 9, Day 1 | -6.9 ± 26.33 | -6.7 ± 24.22 |
| Cycle 11, Day 1 | -0.5 ± 25.58 | -5.2 ± 25.38 |
| Cycle 13, Day 1 | -1.0 ± 25.05 | -1.7 ± 22.24 |
| Cycle 15, Day 1 | -4.9 ± 26.09 | 0.5 ± 23.56 |
| Cycle 17, Day 1 | -5.1 ± 24.91 | -7.7 ± 21.55 |
| Cycle 19, Day 1 | -1.3 ± 19.51 | 0.8 ± 26.09 |
| Cycle 21, Day 1 | -6.6 ± 26.16 | -5.6 ± 20.01 |
| Cycle 23, Day 1 | -2.9 ± 23.20 | -1.0 ± 22.99 |
| Cycle 25, Day 1 | -4.7 ± 26.29 | -4.5 ± 24.68 |
| Cycle 27, Day 1 | -9.0 ± 24.46 | 4.2 ± 26.70 |
| Cycle 29, Day 1 | -6.9 ± 24.67 | -1.1 ± 26.33 |
| Cycle 31, Day 1 | -4.8 ± 26.48 | 5.6 ± 35.36 |
| Cycle 33, Day 1 | -7.7 ± 27.22 | -7.1 ± 22.79 |
| Cycle 35, Day 1 | -3.8 ± 24.03 | 4.2 ± 29.23 |
| Cycle 37, Day 1 | -13.7 ± 29.86 | 10.4 ± 12.50 |
| Cycle 39, Day 1 | -9.3 ± 28.05 | 0.0 ± 0.00 |
| Cycle 41, Day 1 | -11.0 ± 30.47 | 8.3 ± 8.33 |
| Cycle 43, Day 1 | 2.0 ± 28.95 | -8.3 ± 23.57 |
| Cycle 45, Day 1 | -1.7 ± 33.75 | 4.2 ± 5.89 |
| Cycle 47, Day 1 | 10.4 ± 22.95 | -8.3 |
| Final visit | -8.1 ± 26.40 | -6.7 ± 28.50 |
PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.
| T-score | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Cycle 3, Day 1 | 2.2 ± 9.54 | 1.8 ± 8.12 |
| Cycle 5, Day 1 | 3.3 ± 9.25 | 2.4 ± 10.34 |
| Cycle 7, Day 1 | 3.2 ± 9.28 | 2.6 ± 9.70 |
| Cycle 9, Day 1 | 2.3 ± 8.90 | 2.6 ± 8.67 |
| Cycle 11, Day 1 | 0.6 ± 8.54 | 3.1 ± 8.98 |
| Cycle 13, Day 1 | 1.8 ± 8.03 | 2.3 ± 6.97 |
| Cycle 15, Day 1 | 1.5 ± 8.84 | 2.1 ± 7.66 |
| Cycle 17, Day 1 | 1.2 ± 8.11 | 2.6 ± 8.05 |
| Cycle 19, Day 1 | 0.7 ± 8.52 | 0.9 ± 9.32 |
| Cycle 21, Day 1 | 1.6 ± 8.58 | 1.2 ± 7.66 |
| Cycle 23, Day 1 | 2.0 ± 8.08 | 1.5 ± 8.83 |
| Cycle 25, Day 1 | 2.0 ± 8.59 | -0.1 ± 8.73 |
| Cycle 27, Day 1 | 3.4 ± 8.19 | -0.1 ± 9.59 |
| Cycle 29, Day 1 | 3.9 ± 8.07 | 0.8 ± 8.51 |
| Cycle 31, Day 1 | 2.8 ± 8.43 | -0.3 ± 9.15 |
| Cycle 33, Day 1 | 2.0 ± 8.93 | 3.7 ± 9.17 |
| Cycle 35, Day 1 | 3.4 ± 9.27 | 1.1 ± 7.22 |
| Cycle 37, Day 1 | 4.1 ± 9.72 | -3.0 ± 11.72 |
| Cycle 39, Day 1 | 3.6 ± 8.12 | 4.1 ± 2.82 |
| Cycle 41, Day 1 | 3.3 ± 8.69 | -0.7 ± 6.90 |
| Cycle 43, Day 1 | 5.3 ± 9.28 | 4.4 ± 1.91 |
| Cycle 45, Day 1 | -0.3 ± 7.99 | 1.8 ± 0.28 |
| Cycle 47, Day 1 | -2.5 ± 6.30 | 0.0 |
| Final visit | 5.0 ± 10.95 | 2.9 ± 9.96 |
OS is defined as the number of days from the date of randomization to the date of death due to any cause. All events of death were to be included, regardless of whether the event occurred while the participant was still taking study drug or after the participant discontinued study drug. If a participant is not known to have died, OS was censored at the date of last contact. The distribution of OS was estimated using Kaplan-Meier methodology.
| months | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Overall Survival (OS). | NA (44.4 to NA) | NA (44.0 to NA) |
TTP is defined as the number of days from the date of randomization to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan-Meier methodology.
| months | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Time to Progression (TTP) | 25.4 (20.6 to NA) | 12.2 (9.9 to 15.0) |
Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC).
| percentage of participants | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Overall Response Rate (ORR) | 81.4 (75.2 to 86.7) | 69.1 (58.9 to 78.1) |
MRD negativity rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any time point after randomization and before progression or starting subsequent therapy. MRD negativity was defined at 10\^-5 threshold (less than one residual myeloma cell per 10\^5 total nucleated cells) as measured by centralized testing of bone marrow aspirate by Next Generation Sequencing (NGS). MRD positive participants include those of which all tested samples were found to be MRD positive or indeterminate. Participants with missing or unevaluable MRD status were considered as MRD positive.
| percentage of participants | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| Minimal Residual Disease (MRD) Negativity Rate | 15.5 (10.7 to 21.3) | 2.1 (0.3 to 7.3) |
Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was 48.4 months for the venetoclax group and 47.2 months for the placebo group. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean time on venetoclax was 582.2 days and mean time on placebo was 431.3 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Venetoclax + Bortezomib and Dexamethasone | 81/194 (41.8%) | 115/193 (59.6%) | 191/193 (99%) |
| Placebo + Bortezomib and Dexamethasone | 36/97 (37.1%) | 53/96 (55.2%) | 95/96 (99%) |
| Event | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| PNEUMONIAInfections and infestations | 35/193 | 14/96 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/193 | 5/96 |
| INFLUENZAInfections and infestations | 3/193 | 4/96 |
| CATARACTEye disorders | 3/193 | 3/96 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 3/193 | 3/96 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 3/193 | 3/96 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 6/193 | 0/96 |
| COVID-19 PNEUMONIAInfections and infestations | 6/193 | 1/96 |
| SEPSISInfections and infestations | 6/193 | 0/96 |
| ORTHOSTATIC HYPOTENSIONVascular disorders | 5/193 | 2/96 |
| Event | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 114/193 | 46/96 |
| NAUSEAGastrointestinal disorders | 73/193 | 22/96 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 53/193 | 34/96 |
| CONSTIPATIONGastrointestinal disorders | 68/193 | 29/96 |
| FATIGUEGeneral disorders | 63/193 | 31/96 |
| NEUROPATHY PERIPHERALNervous system disorders | 59/193 | 27/96 |
| INSOMNIAPsychiatric disorders | 56/193 | 29/96 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 55/193 | 25/96 |
| NEUTROPENIABlood and lymphatic system disorders | 54/193 | 9/96 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 36/193 | 24/96 |
Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization
| Age, Continuous(years) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| Mean | 65.9 ± 9.41 | 65.9 ± 7.81 | 65.9 ± 8.90 |
| Sex: Female, Male(Participants) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| Female | 97 | 42 | 139 |
| Male | 97 | 55 | 152 |
| Ethnicity (NIH/OMB)(Participants) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 7 | 32 |
| Not Hispanic or Latino | 169 | 90 | 259 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 59 | 28 | 87 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 3 | 12 |
| White | 124 | 66 | 190 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Time since diagnosis(days) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| Median | 1263.5 (62.0 to 8356.0) | 1461.0 (195.0 to 4906.0) | 1318.0 (62.0 to 8356.0) |
| Number of prior lines of therapy(number of prior lines of therapy) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| Median | 1.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 3.0) |
| Number of prior lines of multiple myeloma therapy(Participants) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| 1 line | 91 | 44 | 135 |
| 2-3 lines | 103 | 53 | 156 |
| Prior exposure to proteasome inhibitors (PI)(Participants) | Venetoclax + Bortezomib and Dexamethasone | Placebo + Bortezomib and Dexamethasone | Total |
|---|---|---|---|
| Refractory | 0 | 2 | 2 |
| Sensitive | 131 | 66 | 197 |
| Naïve | 61 | 28 | 89 |
| Unknown | 2 | 0 | 2 |
| MISSING | 0 | 1 | 1 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jul 2016 to primary completion in Mar 2021, 56 months.
Results were first posted in Aug 2023, 2 years 5 months after primary completion. A results delay was requested in Jul 2021.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 56 months is above that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax